Health Care · Surgical & Medical Instruments & Apparatus

PLSE PULSE BIOSCIENCES, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 162510197 filings
Russell 2000

PLSE at a glance

PULSE BIOSCIENCES, INC. (PLSE, SEC CIK 1625101) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350,000 and a net loss of $72.8 million. Diluted EPS was -$1.08.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding PULSE BIOSCIENCES, INC. (PLSE) shares worth $525.8 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Teplitsky Liane Rae on September 1, 2026 of 1,001 shares at $49.95 per share.
  • In the last 90 days, PLSE insiders reported 4 open-market purchases ($200K) and 0 open-market sales ($0) on Form 4, a net purchase of $200K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$350K
10-K XBRL
Insiders · 90 days
4 buys · 0 sells
Net +$200K
13F holders
25 funds
$525.8M · +1 vs prior quarter
Latest 8-K
Nov 6, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0.4M, up $0.3M YoY from $0.1M, entirely from limited Vybrance sales
  • Operating margin not disclosed; operating loss $24.3M vs $20.4M YoY
  • Vybrance best-performing product line, revenue $0.4M versus $0.1M YoY
  • Cash, equivalents and marketable securities $189.2M; operating cash use $48.6M for nine months
  • Management expects additional losses, plans near-term capital raising, cites financing access and market conditions as headwinds

Risk Factors

  • New AI compliance risk triggered by expanded internal use of generative AI and machine learning, including EU AI Act and evolving FDA requirements
  • Regulatory review delays heightened by FDA workforce reductions, voluntary departures, and policy uncertainty since January 2025
  • Near-term adoption risk: surgeons have been slow to adopt the Vybrance System due to limited clinical data and reimbursement uncertainty
  • Liquidity risk: additional capital required, with armed conflicts and tariffs potentially restricting financing availability or increasing dilution
  • Cybersecurity risk: limited resources and no redundant information technology across all systems increase vulnerability to disruptive incidents

AI summary of the PLSE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 6, 2026Full analysis →

Item 8.01: Other Events

  • Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules
  • 86% achieved the primary endpoint, at least 50% nodule-volume reduction

Item EX-99.1: Item EX-99.1

  • Interim six-month PRECISE-BTN results support clinical efficacy: 86% of 43 evaluated patients achieved at least 50% nodule reduction
  • Median nodule volume reduction reached 72%, with improvement beginning by one month after a single treatment
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter ended September 30, 2026 results announced
  • Financial and operational details provided in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $0.4M versus $0.1M, but controlled Vybrance launch continues through Q4 2027
  • NANOPULSE-AF enrollment complete: 169 evaluable patients across 15 sites, three months ahead of plan
Filed Oct 14, 2026Full analysis →

Item 8.01: Other Events

  • Commercial and clinical partnership with Clayman Thyroid Center and affiliates in Tampa, Florida
  • Partnership will evaluate clinical utility of Pulse’s proprietary nPulse Vybrance Percutaneous Electrode System

AI summaries of PLSE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PLSE

Don't miss the next PLSE filing

  • Alerts as it files. A push when PLSE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PLSE, by share count.
  • Ask anything. An AI agent that reads every PLSE filing and answers with sources.

PLSE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Teplitsky Liane RaeBuySep 1, 2026$49.95
Teplitsky Liane RaeBuyAug 31, 2026$48.80
Teplitsky Liane RaeBuyAug 28, 2026$48.35
Teplitsky Liane RaeBuyAug 26, 2026$48.23
Teplitsky Liane RaeAAug 8, 2026-
Teplitsky Liane RaeAAug 8, 2026-
Zanganeh MahkamAJun 11, 2026-
Sainz MariaAJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$350K
Operating Income--$56.3M-$76.9M
Net Income-$42.2M-$53.6M-$72.8M
Op. Margin---21982.6%
Net Margin---20794.6%
Balance Sheet
Total Assets$59.2M$132.5M$94.5M
Equity-$114.9M$80.7M
ROE--46.7%-90.2%
Per Share
EPS$-0.88$-0.92$-1.08
Cash Flow
Operating CF--$36.3M-$54.1M
CapEx$121K$125K$315K

Source: XBRL data in PULSE BIOSCIENCES, INC. (PLSE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PLSE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PLSE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$525.8M
Q2 202624$175.2M
Q1 202619$91.3M
Q4 202515$56.7M
Q3 202517$72.0M
Q2 202518$63.9M
Q1 202518$43.4M
Q4 202412$38.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PLSE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 6, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 14, 2026Analysis-
8-KOct 7, 2026Analysis-
8-KSep 15, 2026Analysis-
8-KSep 15, 2026Analysis-
4Sep 2, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KJul 29, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 12, 2026Analysis-
8-KJun 10, 2026Analysis
10-QMay 14, 2026Analysis
4May 11, 2026-
4May 11, 2026-

Related Health Care companies

All Health Care →

PLSE SEC filings: frequently asked questions

Are PLSE insiders buying or selling?

In the last 90 days, PULSE BIOSCIENCES, INC. (PLSE) officers, directors and 10% owners reported 4 open-market purchases worth $199,937 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PLSE stock?

As of September 30, 2026, the largest PULSE BIOSCIENCES, INC. (PLSE) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($139.3 million), BlackRock ($83.6 million), Citadel Advisors LLC ($74.1 million), Bank of America Corp ($73.2 million), Vanguard Capital Management LLC ($46.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PLSE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350,000 and a net loss of $72.8 million. Diluted EPS was -$1.08. The figures come from the XBRL data in the 10-K.

What did PLSE report in its latest 8-K?

PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K on November 6, 2026 reporting Item 8.01 (Other Events). Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules.

What are the latest PLSE SEC filings?

PULSE BIOSCIENCES, INC. (PLSE) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on September 2, 2026.

What is PLSE's SEC CIK number?

PULSE BIOSCIENCES, INC. (PLSE)'s SEC Central Index Key (CIK) is 1625101. EDGAR lists every PLSE filing under that number.

Ask anything about PLSE

The research agent reads PLSE's filings, financials, insider trades and 13F holders, then answers with sources.